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Degeneration in arousal neurons in 
chronic sleep disruption modeling 
sleep apnea
Yan Zhu, Polina Fenik, Guanxia Zhan, Ryan Xin and Sigrid C. Veasey *
Center for Sleep and Circadian Neurobiology, Department of Medicine, Perelman School of Medicine, University of 
Pennsylvania, Philadelphia, PA, USA
Chronic sleep disruption (CSD) is a cardinal feature of sleep apnea that predicts impaired 
wakefulness. Despite effective treatment of apneas and sleep disruption, patients with 
sleep apnea may have persistent somnolence. Lasting wake disturbances in treated sleep 
apnea raise the possibility that CSD may induce sufficient degeneration in wake-activated 
neurons (WAN) to cause irreversible wake impairments. Implementing a stereological 
approach in a murine model of CSD, we found reduced neuronal counts in representative 
WAN groups, locus coeruleus (LC) and orexinergic neurons, reduced by 50 and 25%, 
respectively. Mice exposed to CSD showed shortened sleep latencies lasting at least 
4 weeks into recovery from CSD. As CSD results in frequent activation of WAN, we 
hypothesized that CSD promotes mitochondrial metabolic stress in WAN. In support, CSD 
increased lipofuscin within select WAN. Further, examining the LC as a representative WAN 
nucleus, we observed increased mitochondrial protein acetylation and down-regulation 
of anti-oxidant enzyme and brain-derived neurotrophic factor mRNA. Remarkably, CSD 
markedly increased tumor necrosis factor-alpha within WAN, and not in adjacent neurons 
or glia. Thus, CSD, as observed in sleep apnea, results in a composite of lasting wake 
impairments, loss of select neurons, a pro-inflammatory, pro-oxidative mitochondrial stress 
response in WAN, consistent with a degenerative process with behavioral consequences.
Keywords: sleep fragmentation, wakefulness, neurodegeneration and neural differentiation, norepinephrine, 
hypocretins/orexins
introduction
All individuals with untreated obstructive sleep apnea experience chronic sleep disruption (CSD), and 
this feature of sleep apnea is considered an important source of impaired wakefulness (1, 2). While 
most patients successfully treated have marked improvements in hypersomnolence, many effectively 
treated individuals experience refractory or persistent wake impairments (3). The mechanisms by 
which hypersomnolence persists in treated apnea are not known. Plausible explanations include 
metabolic derangements, particularly in obese patients, depression, and additional sleep disorders. 
An alternative explanation for residual sleepiness in treated sleep apnea is that CSD might injure 
neurons responsible for optimal alertness sufficiently enough to manifest as lasting wake impairments.
Diverse neuronal groups, and potentially glia, influence sleep and wakefulness (4–6). Within this 
complex circuitry are subsets of neurons that are activated upon arousal and in turn modulate wakeful-
ness. These wake-activated neurons (WAN) groups include the noradrenergic locus coeruleus (LC), 
orexinergic, histaminergic neurons, and also specific cholinergic, serotoninergic, and dopaminergic 
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nuclei. While sufficient loss of orexinergic neurons causes narco-
lepsy, loss of one or more of the other wake modulatory groups has 
little effect on total wake time (7), yet may have profound effects 
on attention and vigilance and the ability to sustain wakefulness 
(8, 9). Thus, it is anticipated that injury to these wake modulatory 
WAN would impair aspects of wakefulness.
Wake-activated neurons typically project extensive collaterals 
and produce large quantities of neuromodulators and/or neu-
rotransmitters (10, 11). Thus, the neurons have high metabolic 
demands under normal conditions, and are susceptible to meta-
bolic stress upon increased activation or metabolic perturbances 
(12–14). We recently found that adult mice exposed to 4 weeks 
of CSD developed impaired arousal responses and blunted WAN 
activation responses that might contribute to arousal responses 
(15). To extend these findings, we sought to determine first whether 
CSD could result in degeneration of WAN, impart lasting wake 
impairments and to then explore mechanisms of injury. Having 
recently identified mitochondrial metabolic stress as a source of 
injury in chronic short sleep (16), we determined whether CSD 
would also manifest as mitochondrial metabolic stress in WAN. 
Tumor necrosis factor-alpha (TNF-α) is up-regulated in the brains 
of animals’ models of sleep fragmentation and short sleep (17, 18). 
The source of TNF-α is presumed to be glial, yet this has not been 
confirmed, and there are reports of neuronal TNF-α (19, 20). In the 
present studies, we examined TNF-α responses in WAN nuclei. A 
complement of electrophysiologic, neuroanatomic, and molecular 
approaches was implemented to characterize WAN metabolic and 
inflammatory responses to CSD and the lasting consequences of 
CSD on wakefulness and wake neuron survival.
Materials and Methods
Mice and study Overview
Studies were performed at the University of Pennsylvania with the 
approval of the Institutional Animal Care and Use Committee and 
in accordance with the revised National Institutes of Health Office 
Laboratory Animal Welfare Policy. C57/BL6 male mice (Jackson 
Laboratory) were 8 weeks of age at the start of experimentation. 
Four B6.129S-Tnftm1Gkl/J (TNF-α−/−) male mice were used as 
negative controls in TNF-α immunohistochemical studies. Studied 
mice were born in our colony and were continually housed in a 
light/dark environment (lights-on from 6 a.m. to 6 p.m.) and fed 
ad libitum standard rodent chow and water. Ambient temperature 
and humidity were maintained between 22–24°C and 40–60%, 
respectively.
chronic sleep Disruption Protocol
Mice were randomized to receive 14 weeks of CSD or control (Ctl) 
conditions. CSD was performed across the entire 24 h period to 
ensure total sleep fragmentation (as observed in sleep apnea) and 
to avoid having the mice increase sleep during their habitual active 
period, thereby changing their circadian rhythms. Previously, we 
have shown that total sleep time and sleep distribution across 
24  h are unchanged in this paradigm, while arousal frequency 
is doubled (15). CSD was induced using methods designed and 
initially validated by Sinton et al. (21) using an orbital rotor (MaxQ 
2000; Thermo Scientific, Marietta, OH, USA) with speed set at 
110 rpm, and a repeated cycle of 10 s-on, 50 s-off continuously 
across 14 weeks controlled by a timer (H3CR-F8-300, OMRON 
Corporation, Kyoto, Japan). An auditory stimulus used in the 
Sinton model was omitted to avoid awakening Ctl mice. A target 
arousal frequency of 60/h was chosen to double the arousal 
frequency in mice. Ctl mice were exposed to 2 h of rotor motion 
continuously for the first 2 h of the dark period to experience a 
similar number of rotations/day, yet to avoid sleep disruption. 
Standard mouse cages were placed on enlarged rotor platforms 
(65  cm ×  120  cm). Mice under CSD and Ctl conditions were 
able to groom, eat, and drink during orbital rotor movement of 
the platform. Water bottles with long nozzles equipped with ball 
valve tips were used to prevent leakage with platform movement. 
Previously, we established that mice maintained in these conditions 
over prolonged periods gain weight normally and do not manifest 
increased plasma corticosteroid levels (15).
Surgery and Behavioral State Recording and Analysis
A subset of mice was examined for sleep/wake effects following 
14 weeks CSD and a 4-week recovery period (n = 8) or Ctl condi-
tions (n = 7). For chronic sleep recording electrode implantation, 
mice were removed from the CSD and Ctl conditions for 2 weeks 
and then anesthetized with ketamine (90–100 mg/kg) and xylazine 
(10  mg/kg) and implanted as previously described with fronto-
cortical electroencephalographic (EEG), occipital ground, and dorsal 
nuchal electromyographic (EMG) recording wires and electrode 
connector (22). Following a 1-week post-operative period, mice were 
connected to a counterweighted recording cable. At 4 weeks into 
recovery from CSD or Ctl conditions, electrographic signals were 
amplified, digitized, and recorded and exported into the SleepSign 
sleep/wake program (version 3.0, Kissei) for analysis. Wake–sleep 
states were scored in 4 s epochs, using recently detailed criteria for 
state determination. As CSD effects on sleep parameters have recently 
been described, including use of our paradigm (15, 23), we focused 
the present analysis on wake parameters: 24 h total wake time and 
hourly distribution and latencies to sleep in the active period (dark 
onset period) and sleep-predominant (lights-on) period. Data were 
analyzed using one- and two-way ANOVA, corrected for multiple 
comparisons using Sidak’s for the three behavioral states.
Immunohistochemistry
Histological studies were performed for optical fractionator 
stereological counts and for characterization of WAN injury. 
Mice exposed to CSD and Ctl conditions (n =  5–6/group, all 
after the 4-week recovery) were anesthetized with pentobarbital 
for transcardial perfusion with 4% paraformaldehyde. Post-fixed, 
cryoprotected brains were sectioned coronally at 60 μm for 1:6 
section series of the complete brain (24). From the 1:6 series, a 
1:2 rostral–caudal complete set of orexinergic and a 1:3 set of 
noradrenergic LC neurons were selected for optical fractionator 
stereological counts. Primary antibodies details and titers were 
recently reported (24). Visualization of target antigens was per-
formed using Vector Blue labeling (Vector Laboratories) of orexin 
or tyrosine hydroxylase (TH) immunolabeled neurons and coun-
terstained with Giemsa for detection of all neurons and their nuclei 
within the counting frame. Using a Nikon Eclipse 600 microscope 
and a Stereo Investigator workstation (MicroBrightField), an 
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optical fractionator approach (25) was validated to estimate the 
total number of LC and orexinergic neurons per mouse. For LC 
neuron counts, all Giemsa labeled somata >15 μm diameter within 
the LC nucleus with a nucleus that came into focus within the 
counting frame (probe) were counted using a 100× oil objective. 
A sampling scheme of 0.25 area sampling frequency for LC and 
0.16 for orexinergic neurons with a thickness sampling frequency 
of 0.79 (allowing 2 μm guard zones on either side) were used. 
In preliminary studies implementing wild-type rested mice, this 
strategy provides >150 counts/mouse and Gundersen coefficients 
of error <0.10. For orexinergic neuron number estimates, only 
orexinergic-labeled neurons with visible nuclei were included. By 
performing counts after a 4-week recovery period, we reasoned 
that if short-term down-regulation of orexin in neurons contrib-
utes to reduced counts that this would be resolved after a 4-week 
recovery opportunity. Neuronal counts were averaged across two 
counters (>90% agreement) and analyzed using one-way ANOVA 
and Sidak’s multiple comparisons test for the two WAN groups.
Noradrenergic and orexinergic WAN and melanin-concen-
trating hormone (MCH) sleep-active neurons were examined 
for lipofuscin analyzed for autofluorescence intensity (excitation 
488 nm, emission 550–650 nm) and Alexa Fluor 488 labeling of 
WAN. Anti-MCH (H-070-47, Phoenix Pharm) at 1:1000 was used 
to identify MCH neurons. Noradrenergic, orexinergic, MCH, and 
histaminergic neurons were examined for TNF-α normalized 
immunointensities. TNF-α was detected using with 3707, Cell 
Signaling at 1:2000. Histaminergic neurons were targeted for 
visualization with anti-histidine decarboxylase antibody (B-GP-
265-1, Euro-diagnostica, 1:1000). Each neuronal population was 
visualized with Alexa Fluor 594 and TNF-α with 488 (Invitrogen). 
Imaging was performed using a SP5/AOBS confocal microscope; 
for confocal image acquisition, laser intensities and frequencies, 
exposure time, detector gain, amplifier offset, and depth of the focal 
plane within the section were standardized to allow comparison 
across sections (24). Both lipofuscin and TNF-α were analyzed 
using one-way ANOVA for sleep condition with Sidak’s multiple 
comparison test for three or four WAN groups.
Brain Tissue Procurement, Mitochondrial Isolation,  
and Westerns
Additional groups of mice (CSD and Ctl groups + recov, n = 5–12/
group) were used for protein and RNA studies. These mice were 
anesthetized and transcardially perfused with ice-cold phospho-
buffered saline with RNase inhibitor. Brains were rapidly removed 
and sectioned coronally for tissue punches (1 mm3) of LC bilater-
ally and stored in −70°C. Mitochondria isolation and cytosolic 
fractionation were performed using a commercial mitochondria 
isolation kit (#89801, Thermo Scientific) according to manufac-
turer’s recommendations using their Dounce homogenization 
protocol. Mitochondria-enriched samples were verified with a 
mitochondrial-specific protein, voltage-dependent anion channel 1 
(VDAC1). Total lysine-acetylated protein were analyzed using our 
previously published western blot protocol (24) using 9441, Cell 
Signaling at 1:500. Images were analyzed with Odyssey Application 
software, version 3.0.16 (Li-Cor), for mean integrated densities that 
were normalized to VDAC1 and analyzed with unpaired t-test for 
the one variable.
Quantitative Real-Time PCR
Quantitative real-time PCR was performed on LC and LH 
punches to examine mitochondrial sirtuin type 3 (SirT3), TNF-α, 
brain-derived neurotrophic factor (BDNF, total), catalase, and 
SOD2 transcriptional responses to short-term sleep loss in CSD 
and Ctl mice (n = 5–10/group) using recently detailed methods 
(24). Sequences for some of Taqman primer/probe sets, designed 
using Primer Express 2.0.0 software, are detailed in previous 
papers: SirT3, SOD2, and catalase (16), TH, dopamine beta-
hydroxylase (DBH), and orexin (24). For BDNF (NM_007540), 
we used sense: GGGTCACAGCGGCAGATAA (1107–1125); 
anti-sense: TGCAGCCTTCCTTGGTGTAAC (1256–1236); 
and probe: TCCCGGTATCCAAAGGCCAACT (1176–1197). 
Primer/probe sets showed excellent sensitivity (detection of 
>104 copies/sample) and Ct vs. log copies linearity (r2 > 0.99). 
Copy numbers were analyzed using two-way ANOVA for gene 
and sleep condition, with multiple comparisons corrected using 
Sidak’s–Bonferroni t-test.
results
csD imparts lasting Wake impairments, 
Without influencing Total sleep Time
There were no differences in total sleep time following CSD and Ctl 
conditions, t = 1.1, N.S. These data are summarized in Figure 1A. 
FigUre 1 | effects of rotor platform chronic sleep disruption (csD) on 
wakefulness. (a) Group data during CSD for total sleep time across 24 h in 
control (Ctl, black bar, n = 7 mice) and CSD (gray bar, n = 8 mice). Data 
shown are mean ± SE values. (B) Group sleep latencies following CSD or Ctl 
conditions and a 4-week recovery period (normal sleep conditions). 
Mean ± SE are presented for the lights-on (light gray bars) and lights-off 
(black bars), ***p < 0.001. (c) Hourly percentiles of time spent in wakefulness 
across the 24-h light–dark cycle, denoted as Zeitgeber time relative to 
lights-on onset. Data are mean ± SE for CSD (red circles) and Ctl mice (blue 
circles). *p < 0.05 for multiple t-test significances for each hour, as detailed in 
results. Light blue x-axis bar denotes lights-on and dark bar lights-off periods.
FigUre 2 | reduced neuron estimates for locus coeruleus (lc) and 
orexinergic neurons in csD. (a) Optical fractionator stereological bilateral 
count estimates on 1:3 series of LC sections/mouse for mice exposed to Ctl 
(black bar) or CSD (gray bar) conditions obtained after a 4-week recovery 
opportunity for both groups (n = 5/group), **p < 0.01. (B) A similar 
stereological approach was used on a 1:2 series of orexinergic neuron 
sections/mouse for mice exposed to Ctl (black bar) or CSD (gray bar) 
conditions obtained after a 4-week recovery opportunity for both groups 
(n = 5/group), **p < 0.01. (c) Upper panels, representative images from mid 
LC in a Ctl (left) mouse and CSD mouse (right), immunolabeled with tyrosine 
hydroxylase (TH) and substrate blue. All TH+ and TH− cells are stained with 
Giemsa to provide nuclear details for counts and to identify non-TH neurons 
in LC nuclei. Calibration bar, 100 μm. Lower panels, similarly obtained 
images of perifornicular orexinergic neurons in Ctl and CSD mice. Calib bar, 
200 μm. Note in CSD mice, both LC and orexinergic remaining neuronal 
somata are significantly smaller.
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Previous studies by multiple groups have highlighted shortened 
sleep latencies immediately following CSD. Here, we sought to 
determine whether 4-week recovery time in home cages resting 
unperturbed is sufficient to fully reverse shortened sleep laten-
cies. Mice exposed to CSD and then allowed a 4-week recovery 
opportunity were assessed for sleep latencies at lights-on and 
lights-off. Overall, there were significant CSD and circadian time 
differences, F = 16.5, p < 0.0001, as summarized in Figure 1B. 
Ctl mice demonstrated a longer sleep latency for the lights-off 
period, relative to lights-on, t = 4.9, p < 0.001. In contrast, CSD 
mice showed no difference in sleep latency for the lights-off and 
-on periods, t = 1.5, N.S. There was no effect of CSD on the sleep 
latency for the lights-on period, t = 1.7, N.S.; however, there was 
a significant reduction in the sleep latency for CSD mice relative 
to rested for the lights-off period, t = 5.0, p < 0.001. Examining 
the hourly distribution of wake time across a 24-h period, there 
were three times (corrected for 24 comparisons) within the active 
period that CSD mice showed reduced wake times, as summarized 
in Figure 1C. In all CSD mice, the wake period at lights-off was 
significantly shorter. Thus, CSD using this paradigm results in 
lasting effects on sleep latencies and wake times during the active 
(lights-off period).
Wake-activated neuron loss in csD
Previously, we observed reduced numbers of catecholaminergic 
(TH+) and orexinergic (orexin+) projections to the frontal cortex 
in mice exposed to CSD (15). Here, we sought to extend findings 
to LC and orexinergic neuron survival. To exclude the possibility 
that CSD temporarily down-regulates neuronal markers, e.g., TH 
for LC and orexin for orexinergic neurons, we performed neuronal 
counts after 4 weeks recovery from CSD or Ctl, allowing mice to 
sleep in home cages unperturbed for the 4-week (n = 5–6/condi-
tion). Overall, there were significant effects of CSD on LC and 
orexin neuron counts, F = 11.4, p < 0.001. Relative to Ctl mice, 
LCn counts were reduced by 50% in CSD, t = 4.2, p < 0.001 as 
summarized in Figure 2A. We next examined the effect of CSD 
on orexinergic neurons and found that CSD resulted in a 25% loss 
of orexinergic neurons relative to age-matched Ctl mice, t = 2.4, 
p < 0.05, Figure 2B. Examination of the remaining neurons for 
both LC and orexinergic neurons revealed smaller WAN with 
fewer dendritic projections, consistent with previous findings, as 
illustrated in Figure 2C. Thus, CSD results in degeneration of LC 
and orexinergic WAN.
Metabolic compromise in surviving neurons
Having identified mitochondrial metabolic compromise in LC 
neurons in mice exposed to repeated episodes of short sleep 
(16), we next examined whether CSD (without sleep curtail-
ment) also imparts metabolic stress in WAN mitochondria. 
Cardinal features of mitochondrial stress include oxidative stress 
and hyperacetylation of mitochondrial proteins. Lipofuscin 
is comprised of, in part, effete mitochondrial debris within 
lysosomes. The accreted material emits oxygen radicals and 
is a marker of significant oxidative stress (26). Lipofuscin has 
autofluorescence allowing detection with fluorescent microscopy 
in tissue samples processed with little Triton. Lipofuscin was 
markedly increased in LC neurons of mice exposed to CSD, 
t = 3.0 and p < 0.05, as shown in Figure 3A. Similarly lipofuscin 
increased in orexinergic neurons in response to CSD, t = 4.3 
and p < 0.001, as shown in Figures 3A,B. To determine whether 
the observed CSD-increase in lipofuscin is specific to WAN, we 
measured lipofuscin in sleep-active MCH neurons and found 
no increase in lipofuscin in MCH neurons in mice exposed to 
CSD, t = 0.1, N.S., Figure 3A. Thus, CSD increases lipofuscin 
in LC and orex WAN without influencing the orexin-adjacent 
sleep-active group, MCH.
FigUre 3 | Metabolic dyshomeostasis in Wan in csD. (a) Group 
lipofuscin autofluorescence intensity (excitation 488, emission 550–650) for 
LC, orexin, and melanin-concentrating hormone (MCH) neurons in mice 
exposed to Ctl (black bars) and CSD (gray bars). Data are presented as 
mean ± SE for n = 5–7/group, *p < 0.05; ***p < 0.001. (B) Representative 
images of autofluorescence (yellow) in sections from Ctl (upper) and CSD 
(lower) mice in LC neurons. DAPI (blue) labels nuclei within the sections. TH 
labeling is omitted to highlight the distribution of lipofuscin with the LC 
nucleus. (c) Group data (mean ± SE) for lysine-acetylated protein (total) in 
mitochondrial subcellular fractionations from LC nuclei, normalized to 
mitochondrial protein VDAC1 in Ctl (black bar) and CSD (gray bar) (n = 5/
group), **p < 0.01. (D) Representative immunoblots of LC lysine-acetylated 
proteins and VDAC1 in a Ctl (left) and CSD (right) mouse. Kilodalton scale is 
provided for reference. (e) Quantitative RT-PCR data (mean ± SE, n = 7–12/
group) for LC tissue punches from Ctl (black bars) and CSD mice (gray bars). 
Copy numbers were normalized to ribosomal 18S RNA (loading control) and 
then to the scale for all genes. *p < 0.05 in a multiple t-test analysis.
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The LC is a compact population of WAN and thus is suitable 
for tissue punch protein and PCR assays. In contrast, orexinergic 
neurons comprise a minority of lateral hypothalamic neurons. 
Thus, we determined the effects of CSD on mitochondrial protein 
acetylation in LC micropunches. Mitochondrial protein acetylation 
increased significantly in mice exposed to CSD, t = 3.3, p < 0.01, 
Figures 3C,D.
We next measured mRNA responses within the LC nucleus 
to CSD to characterize the oxidative stress response, finding 
marked reductions in mitochondrial sirtuin type 3 (SirT3): 
t = 6.7, and mitochondrial anti-oxidants, superoxide dismutase 
2 (SOD2): t = 6.6, and catalase, t = 5.2. BDNF is essential for 
LC axonal growth in aging and the LC provides BDNF to 
its forebrain targets. CSD resulted in lasting suppression of 
BDNF, t = 2.7 (Figure 3E). Both TH and DBH are necessary 
for noradrenaline production in noradrenergic neurons. CSD 
resulted in robust reductions of both TH: t = 4.1 and DBH: 
t = 3.5, all significant at p < 0.05 for multiple comparisons, 
Figure 3E. Thus, CSD reduces mRNA levels for many proteins 
essential to the metabolic health, growth and maintenance, 
and neuromodulator synthesis.
Up-regulation of Tumor necrosis Factor in 
Wake-activated neurons
A strikingly consistent finding across acute and chronic sleep 
curtailment and short-term and long-term sleep fragmentation 
is up-regulation of TNF-α in the forebrain (27). We hypothesized 
that CSD would increase TNF-α in glia adjacent to WAN and that 
this might contribute to WAN injury. As Breder et al. identified 
TNF-α in neurons in the healthy mouse in a region consistent 
with the histaminergic tuberomammillary WAN (20), we included 
TMN neurons in our analysis. To ensure selectivity of the TNF-
α immunoreactivity, we also studied four TNF-α−/− mice, two 
exposed to CSD and two to Ctl conditions and to determine 
whether the CSD response is specific WAN, we also examined 
TNF-α in MCH neurons. CSD resulted in a marked up-regulation 
of TNF-α within the somata of LCn, t = 8.7, p < 0.0001, as sum-
marized in Figure 4A. TNF-α was also markedly up-regulated 
in the somata of orexinergic neurons of mice exposed to CSD, 
t = 6.5, p < 0.0001, Figure 4B, and TNF-α was similarly increased 
in histaminergic TMN neurons, t = 5.1, p < 0.0001, Figure 4C. 
In contrast, TNF-α was not increased in MCH neurons of mice 
exposed to CSD, t =  0.4, N.S., Figure  4D. There was minimal 
TNF-α signal evident in TNF-α−/− mice, as shown in Figure 4E. 
Thus, CSD results in a substantial increase in TNF-α that appears 
to be specific to WAN without affecting TNF-α in the MCH sleep-
active group of neurons.
Discussion
In health, wakefulness is determined largely by an overlay of sleep 
homeostasis on circadian influences on sleep/wake regulatory 
neuronal groups. This paradigm predicts reversibility in wake 
impairments, which are not always seen in treated obstructive 
sleep apnea. The present findings support the concept that long-
term intermittent disruption of sleep without affecting total sleep 
time is sufficient to injure WAN and that this injury may include 
WAN degeneration and irreversible wake impairments during 
the intended active period of the circadian rhythm. In remaining 
LC and orexinergic WAN, CSD imposed significant oxidative 
stress as evidenced by increasing lipofuscin, while decreasing 
mitochondrial anti-oxidant enzymes, supporting a maladaptive 
response to CSD in these neurons. In addition, there was sig-
nificant mitochondrial metabolic stress as evidenced by increased 
mitochondrial protein acetylation and reduced SirT3. Remarkably, 
CSD resulted in a pronounced and lasting increase in TNF-α in the 
cell bodies of WAN. Collectively, the work provides evidence that 
sleep consolidation is essential for the health and survival of WAN.
Several methods of sleep fragmentation have proven effective in 
the ability to chronically disrupt sleep, and each method has its own 
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strengths and limitations. Methodologies that require the animal 
to ambulate at each intended arousal interval (28) include use of 
a treadmill (28), a sweeper bar that the animal must climb over 
(29), and a rotating floor within a cage (30). Each of these is highly 
effective in inducing arousals at intended intervals. The increased 
locomotor activity, which is not a feature of CSD in sleep apnea, 
may increase neuroprotectants in the brain including SirT1 and 
BDNF (31, 32). The approach developed by Sinton et al. awakens 
mice through postural movement in sleep (21). This movement 
is approximately 70–80% effective in inducing arousals for many 
months. Advantages we perceive with the rotor platform approach 
include that mice may be group housed in their home cages and 
have the opportunity to build and preserve their nests. With this 
paradigm, mice maintain normal circadian sleep/wake patterns, 
and body weights are unaffected by CSD. In contrasts, models of 
12 h CSD across the lights-on period only, mice consistently gain 
weight (33–35). Despite the diverse CSD paradigms, effects on 
sleep and sleep latencies are rather consistent, with most studies 
finding shortened sleep bouts, without reductions in total sleep 
time, and shortened sleep latencies immediately following CSD 
(15, 23, 36, 37). We now extend these findings with the observa-
tions that shortened sleep latencies and reduced wake times in the 
lights-off period persist for at least 4 weeks after return to normal 
uninterrupted sleep; these findings support long-lasting, if not 
irreversible, wake impairments upon CSD.
FigUre 4 | Tumor necrosis factor-alpha (TnF-α) up-regulation in 
Wan. (a–D), TNF-α responses were analyzed for Ctl and CSD mice after 
the 4-week recovery period. Mean ± SE immunointensity of TNF-α within 
cell bodies of Ctl mice (black bars) and CSD mice (gray bar) for (a), LC; 
(B), orexinergic; (c) histaminergic tuberomammillary neurons labeled 
with histidine decarboxylase (HDC); and (D), MCH neurons. 
****p < 0.0001. (e) Representative images of LC neurons in mice 
exposed to Ctl and CSD conditions, including TNF-α−/− mice (right) to 
demonstrate antibody specificity. LC neurons are labeled with TH (red) 
and TNF-α (green).
In the present study, focusing on two groups of WAN, the 
noradrenergic LC and the orexinergic (orex) neurons, we found 
that CSD results in a significant reduction in neuronal counts. Use 
of an optical fractionator stereological approach excludes the pos-
sibility that counts are reduced simply by shrinkage of neurons. By 
examining counts after a 4-week recovery opportunity, we believe 
that the reduced counts are consistent with either neuron death or 
epigenetic re-programing. Our observed reduced transcriptional 
responses would be consistent with either. However, in the LC 
nuclei of CSD mice, there were few TH negative neurons to 
support a significant de-differentiation re-programing. LC and 
orex neuronal counts decline across aging (38–40), and thus, 
one possibility is that CSD accentuates or accelerates the aging 
process within these neurons. In support, we observed increased 
lipofuscin, a marker of cellular senescence. Further studies includ-
ing a more comprehensive aging phenotype (telomere shortening, 
lipid peroxidation, carbonylation, DNA methylation changes, and 
refined timelines of changes) are needed to discern accelerated or 
accentuated aging and delayed reversibility.
In the present study, we focused largely on select popula-
tions of modulatory WAN; however, it is entirely possible 
that other neuronal groups and potentially glia are affected 
by CSD. A human cross-sectional analysis found that CSD in 
older humans is associated with loss within galanin-positive 
neurons in the ventrolateral pre-optic area, many of which are 
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sleep-activated neurons and are important in regulating sleep 
(41). We elected to examine MCH neurons for their proximity 
to orexinergic neurons to better ascertain whether the effects 
of CSD on neurons are predicted by cell type or brain region. 
Although we did not perform stereological counts on MCH 
neurons, we did not observe an effect on lipofuscin, TNF-α, 
or morphology. Thus, we anticipate that neurons activated 
repeatedly upon arousal and those with heightened sensitiv-
ity to metabolic disturbances, such as the LC and orexinergic 
neurons are among subsets of neurons more vulnerable to 
sleep fragmentation.
Examining metabolic responses of LC neurons to CSD, we 
observed increased mitochondrial protein acetylation, a marker 
of impaired SirT3 activity, and mitochondrial metabolic stress. 
In support, SirT3 mRNA levels were markedly reduced in LC 
tissue punches. Additional support for CSD-induced metabolic 
dyshomeostasis in WAN is provided by the increase in lipofuscin 
and the reductions in transcription levels of mitochondrial anti-
oxidant enzymes, superoxide dismutase 2 and catalase, and the 
observed reduction in BDNF mRNA is also consistent with severe 
metabolic stress (32). Thus, CSD imparts metabolic stress to WAN 
while lowering the anti-oxidant response, and in doing so may also 
render these neurons more susceptible to unrelated physiological 
challenges, and at the same time less able to rebuild projections.
We anticipated that, in response to CSD, TNF-α would be 
increased within microglial cells adjacent to WAN, thereby con-
tributing to TNF-α receptor activation-induced neuronal injury 
(31). Remarkably, TNF-α was robustly up-regulated within the 
somata of LC, orexinergic, and histaminergic WAN and not within 
surrounding glia or neurons. Previously, TNF-α immunoreactivity 
was demonstrated in both neuronal cell bodies and neurites within 
regions implicated in metabolism and autonomic function (20) 
and TNF-α can be up-regulated in cortical neurons in an activity-
dependent fashion (19). In the present study, very little TNF-α 
was present in WAN in Ctl mice, while in CSD mice, somatic 
TNF-α was localized exclusively to WAN within regions examined, 
the lateral and posterior hypothalamus and dorsal pons, consist-
ent with increased activation in WAN across CSD. The cellular 
distribution of TNF-α that we observed is quite distinct from the 
groups of neurons in which TNF-α is up-regulated after exposure 
to lipopolysaccharide, where neurons in the ventromedial hypo-
thalamus and dorsal medulla show up-regulation of TNF-α mRNA 
(42). The presence of TNF-α mRNA in neurons supports TNF-α 
synthesis within neurons rather than uptake, while up-regulation 
in distinct neuronal in response to CSD or lipopolysaccharide 
supports the concept that TNF-α neuronal responses vary with 
specific circuit activation. Mechanisms by which TNF-α may be 
up-regulated in response to activation or neuronal metabolics and 
why TNF-α is up-regulated within neurons are not well understood. 
TNF-α receptors can localize to mitochondria (43), and TNF-α 
exposure at physiological levels impairs mitochondrial function 
while increasing the production of reactive oxygen species (44), 
raising the possibility that neuronal TNF-α serves in intraneuronal 
signaling rather than as a cell to cell communicator. We observed 
TNF-α up-regulation well into the recovery period when WAN 
firing should be normalized, yet oxidative stress remained high, 
providing a potential source for the persistent TNF-α levels that, 
in turn, may further injure mitochondria and increase oxidative 
stress. Such a feed forward cycle might explain the lasting wake 
impairments and continued injury in remaining WAN observed 
well into recovery from CSD and deserves further study.
The present collective findings demonstrate that long-term 
fragmentation of sleep without affecting total sleep time is suf-
ficient to induce lasting wake impairments and impose metabolic 
stress with mitochondrial dyshomeostasis and degeneration in, 
at least subsets of, WAN essential for optimal alertness. Clinical 
implications extend beyond obstructive sleep apnea to other 
conditions in which sleep is repeatedly briefly interrupted, such 
as in aging, substance abuse, chronic pain, Parkinson’s disease, 
Alzheimer’s disease, and restless legs syndrome with periodic 
limb movements. The present work has focused on select popula-
tions of WAN. Future directions should include characterizing 
the extent of neuronal injury in the brain and identify specific 
CSD-vulnerable as well as -resistant groups of neurons to facilitate 
elucidation of mechanisms. A longer recovery opportunity may 
be necessary to reverse metabolic and behavioral consequences. 
Additionally, the relative roles of mitochondrial stress and WAN 
TNF-α in WAN injury and degeneration should be determined 
to open therapeutic avenues.
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